Recombinant human interleukin-1 receptor antagonist, as well as composition and medicine application thereof

An interleukin and receptor antagonist technology, which is applied in the directions of drug combinations, pharmaceutical formulations, and non-active ingredients medical preparations, etc., can solve the problems of limited effect and single action mechanism of dry eye syndrome, and achieves low cost and side effects. Small, good lubricating effect on the ocular surface

Inactive Publication Date: 2016-01-06
无锡大周生物工程有限公司
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0009] Therefore, the technical problem to be solved by the present invention is to overcome the defects that the drugs for the treatment of dry eye in the prior art have very limited effects, a single mechanism of action, and are often only temporarily effective for some audiences, thereby providing a drug with good effect and utilization A pharmaceutical composition for the treatment of dry eye with multiple mechanisms and a wide range of applications

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Recombinant human interleukin-1 receptor antagonist, as well as composition and medicine application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0044] The application is used for the preparation of the pharmaceutical composition for treating dry eye syndrome.

[0045] Composition A

[0046] Each 1000ml contains:

[0047] Recombinant human interleukin-1 receptor antagonist 50mg;

[0048] 0.2M, pH 7.0 phosphate buffer solution 120g;

[0049] Dissolve 50 mg of recombinant human interleukin-1 receptor antagonist in 120 g of 0.2 M, pH 7.0 phosphate buffer solution, dilute to 1000 ml with sterile water, and adjust the pH value of the solution to 7.0.

[0050] Composition B

[0051] Each 1000ml contains:

[0052] Recombinant human interleukin-1 receptor antagonist 50mg;

[0053] Chitosan quaternary ammonium salt 120g;

[0054] 120g of 0.2M, pH 7.0 phosphate buffer solution;

[0055] Dissolve 120g of chitosan quaternary ammonium salt in 120g, 0.2M, pH phosphate buffer solution of 7.0, add water equal to the volume of phosphate buffer solution, cool to 4°C, stir and adjust the pH value of the solution to 7.0; The solut...

Embodiment 2

[0066] The application is used for the preparation of the pharmaceutical composition for treating dry eye syndrome.

[0067] Each 1000ml contains:

[0068] Recombinant human interleukin-1 receptor antagonist 40mg;

[0069] Chitosan quaternary ammonium salt 150g;

[0070] Polyethylene glycol 5g;

[0071] 200g of 0.2M, pH 7.0 phosphate buffer solution;

[0072] Dissolve 150g chitosan quaternary ammonium salt and 5g polyethylene glycol in 80g, 0.2M, pH 7.0 phosphate buffer solution, add water equal to the volume of phosphate buffer solution, cool to 4°C, stir to adjust the pH of the solution value to 7.0; heat the solution to 37°C to form a chitosan quaternary ammonium hydrogel solution; add recombinant human interleukin-1 receptor antagonism to the prepared chitosan quaternary ammonium hydrogel solution 40mg dose, dilute to volume with sterile water, and adjust the pH value of the solution to 7.0.

Embodiment 3

[0074] The application is used for the preparation of the pharmaceutical composition for treating dry eye syndrome.

[0075] Each 1000ml contains:

[0076] Recombinant human interleukin-1 receptor antagonist 100mg;

[0077] Chitosan quaternary ammonium salt 50g;

[0078] Polyethylene glycol 9g;

[0079] 150g of 0.2M, pH 7.0 phosphate buffer solution;

[0080] Dissolve 50g chitosan quaternary ammonium salt and 9g polyethylene glycol in 150g, 0.2M, pH 7.0 phosphate buffer solution, add water equal to the phosphate buffer solution, cool to 4°C, stir to adjust the pH of the solution value to 7.0; heat the solution to 37°C to form a chitosan quaternary ammonium hydrogel solution; add recombinant human interleukin-1 receptor antagonism to the prepared chitosan quaternary ammonium hydrogel solution 100mg dose, dilute to volume with sterile water, and adjust the pH value of the solution to 7.0.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
weightaaaaaaaaaa
Login to view more

Abstract

The invention discloses a medicine composition for treating xerophthalmia and a novel purpose of a recombinant human interleukin-1 receptor antagonist to the preparation of medicine for treating xerophthalmia. Experiments prove that the recombinant human interleukin-1 receptor antagonist has a certain effect on the xerophthalmia in various degrees. Compared with the existing antiinflammatory medicine and artificial tear mytear, the medicine composition provided by the invention has an obvious effect. According to the medicine composition for treating the xerophthalmia, water-soluble macromolecular quaternized chitosan is added; the viscosity of the composition is enhanced; the ocular surface is well lubricated; the water-soluble macromolecular quaternized chitosan is combined with the recombinant human interleukin-1 receptor antagonist to a certain degree, so that the activity of the recombinant human interleukin-1 receptor antagonist is protected to a certain degree; and the quaternized chitosan has certain antibacterial performance and histocompatibility, so that the recombinant human interleukin-1 receptor antagonist can be well stored for a long time.

Description

technical field [0001] The invention relates to the field of biopharmaceuticals, in particular to a recombinant human interleukin-1 receptor antagonist and its composition as well as its new application in the field of pharmacy. Background technique [0002] Dry eye refers to the general term for various diseases that are caused by abnormal tear quality or quantity or abnormal dynamics due to tear duct blockage, resulting in decreased tear film stability, accompanied by eye discomfort and ocular surface tissue lesions. Conjunctival xerosis. Common symptoms include dry eyes, easy fatigue, itchy eyes, foreign body sensation, burning pain, sticky secretions, fear of wind, photophobia, and sensitivity to external stimuli; Tears are secreted, resulting in frequent tearing; in severe cases, the eyes will appear red, swollen, hyperemic, and keratinized, and the corneal epithelium will peel off and there will be filaments attached. This kind of damage can cause keratoconjunctival l...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K45/06A61K47/36A61K47/34A61P27/02
Inventor 宋东光苏博洋
Owner 无锡大周生物工程有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap